LARP4 mutations are very rare in cancers compared to well‐known mutated genes such as K‐Ras or p53. The majority of the many somatic mutations present in each cancer probably do not contribute significantly to cancer development, whereas a small subset, called driver mutations, confer clonal selective advantage on the cancer cells and are selected during the evolution of cancer [Nussinov and Tsai, 2015; Pon and Marra, 2015]. This evidence concerns the gene KRAS and cancer.